Amgen, MariTide and weight loss

Amgen starts two critical late-stage trials for weight loss drug MariTide
MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and Eli Lilly.
Amgen starts late-stage studies of MariTide
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese people without diabetes and another one for people with diabetes.
Amgen (NASDAQ:AMGN) Enters Late-Stage Testing on Weight Loss Drug
We know that weight loss drugs have been big winners for the companies that produce them. And now, biotech stock Amgen (AMGN) looks to get in
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly launched trials. | Amgen’s most advanced obesity asset MariTide is entering Maritime—that is,
Amgen Starts Final-Stage Studies of Its Monthly Obesity Drug
Amgen Inc. launched two final-stage studies of its monthly obesity treatment, a closely watched drug that would compete with blockbuster weight-loss medicines from Eli Lilly & Co. and Novo Nordisk A/S.
Amgen begins late-stage trials for obesity therapy
Amgen (NASDAQ:AMGN) has announced the beginning of two Phase 3 studies for its weight loss candidate MariTide as the company aims to take a slice of a burgeoning obesity drug market dominated by Eli Lilly (LLY) and Novo Nordisk (NVO).
Q1 Earnings Forecast for Amgen Issued By William Blair
Research analysts at William Blair issued their Q1 2026 EPS estimates for shares of Amgen in a research note issued on ...
Amgen (NasdaqGS:AMGN) Declares US$2 Dividend Per Share For Q2 2025
Amgen (NasdaqGS:AMGN)'s recent affirmation of a $2.38 per share dividend for Q2 2025 could reflect investor confidence and ...
Fierce Biotech2d
Amgen and CytomX throw off masked T-cell engager, axing asset after assessing data, priorities
Amgen and CytomX Therapeutics have kicked a phase 1 T-cell engager to the curb, axing the asset after assessing the clinical ...
JD Supra1d
Amgen Files Three IPR Petitions Challenging Bristol-Myers Squibb Anti-PD1 and Anti-CTLA-4 Antibody Combination Method of Treatment Patents
Amgen, Inc. (“Amgen”) filed three petitions for inter partes review, challenging the validity of all claims in three patents ...
Dividend Roundup: Nvidia, Amgen, Home Depot, JD.com, and more
This week's dividend activity included increased payouts from Bestbuy (BBY) and JD.com (NASDAQ:JD) as well as declarations ...
Drugmaker Amgen to invest $200 million in India site, CEO says
U.S. drugmaker Amgen will invest about $200 million this year in its new technology centre in southern India, with further ...
AMGEN AND KYOWA KIRIN PROVIDE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 IGNITE STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational ...
Amgen Stock: Why I Still Rate It A 'Buy'
Amgen released financial results for the 4th quarter of 2024. Check out why I continue to cover AMGN stock with a 'Buy' ...
TipRanks on MSN17h
TKO, Nike, Amgen, Macy’s, Marathon: Trending by Analysts
Analysts are intrested in these 5 stocks: ( ($TKO) ), ( ($NKE) ), ( ($AMGN) ), ( ($M) ) and ( ($MARA) ). Here is a breakdown ...